Results from the phase II FIREFLY-1 clinical trial assessing the type-II pan-RAF inhibitor tovorafenib showed high tolerability and strong efficacy in non-Class I BRAF-mutant pediatric low-grade gliomas (pLGG) harboring BRAF structural rearrangements [36]. Here, BRAF is linked to glioma.